
Scientists say it may be possible to protect aging brains from Alzheimer's with an old remedy — lithium
Lithium is best known to medicine as a mood stabilizer given to people who have bipolar disorder and depression. It was approved by the US Food and Drug Administration in 1970, but it was used by doctors to treat mood disorders for nearly a century beforehand.
Now, for the first time, researchers have shown that lithium is naturally present in the body in tiny amounts and that cells require it to function normally — much like vitamin C or iron. It also appears to play a critical role in maintaining brain health.
In a series of experiments reported Wednesday in the journal Nature, researchers at Harvard and Rush universities found that depleting lithium in the diet of normal mice caused their brains to develop inflammation and changes associated with accelerated aging.
In mice that were specially bred to develop the same kinds of brain changes as humans with Alzheimer's disease, a low-lithium diet revved the buildup of sticky proteins that form plaques and tangles in the brains that are hallmarks of the disease. It also sped up memory loss.
Maintaining normal lithium levels in mice as they aged, however, protected them from brain changes associated with Alzheimer's.
If further research supports the findings, it could open the door to new treatments and diagnostic tests for Alzheimer's, which affects an estimated 6.7 million older adults in the United States, according to the US Centers for Disease Control and Prevention.
The research provides a unifying theory that helps explain so many of the puzzle pieces scientists have been trying to fit together for decades.
'It is a potential candidate for a common mechanism leading to the multisystem degeneration of the brain that precedes dementia,' said Dr. Bruce Yankner, a professor of genetics at Harvard Medical School, who led the study. 'It will take a lot more science to determine whether this is a common pathway… or one of several pathways,' to Alzheimer's, he added. 'The data are very intriguing.'
In an editorial published in Nature, Dr. Ashley Bush, a neuroscientist who directs the Melbourne Dementia Research Center at the University of Melbourne in Australia, said the researchers 'present compelling evidence that lithium does in fact have a physiological role and that normal aging might impair the regulation of lithium levels in the brain.' He was not involved in the study.
Close examination of human and animal brain tissues, along with genetic investigations in the study, found the mechanism that appears to be at play: Beta amyloid plaques — the sticky deposits that gum up the brains of Alzheimer's patients — bind to lithium and hold it, including the type that's normally present in the body, as well as the commonly prescribed form. This binding depletes lithium available for nearby cells, including important scavengers known as microglia.
When the brain is healthy and functioning normally, microglia are waste managers, clearing away beta amyloid before it can accumulate and can cause harm. In the team's experiments, microglia from the brains of lithium-deficient mice showed a reduced ability to sweep away and break down beta amyloid.
Yankner believes this creates a downward spiral. The accumulation of beta amyloid soaks up more and more lithium, further crippling the brain's ability to clear it away.
He and his colleagues tested different lithium compounds and found one — lithium orotate — that doesn't bind to amyloid beta.
When they gave lithium orotate to mice with signs of Alzheimer's in their brains, these changes reversed: Beta amyloid plaques and tangles of tau that were choking the memory centers of the brain were reduced. Mice treated with lithium were once again able to navigate mazes and learn to identify new objects, whereas those who got placebos showed no change in their memory and thinking deficits.
In its natural form, lithium is an element, a soft, silvery-white metal that readily combines with other elements to form compounds and salts. It's naturally present in the environment, including in food and water.
Scientists have never fully known how it works to improve mood — only that it does. The original formula for 7Up soda included lithium — it was called 7Up Lithiated Lemon Soda — and touted as a hangover cure and mood lifter 'for hospital or home use.' Some hot springs known to contain mineral water brimming with lithium became sought out wellness destinations for their curative powers.
Still, people who take prescription doses of lithium — which were much higher than the doses used in the new study — can sometimes develop thyroid or kidney toxicity.
Tests of the mice given low doses of lithium orotate showed no signs of damage.
That's encouraging, Yankner said, but it doesn't mean people should try to take lithium supplements on their own.
'A mouse is not a human. Nobody should take anything based just on mouse studies,' Yankner said.
'The lithium treatment data we have is in mice, and it needs to be replicated in humans. We need to find the right dose in humans,' he added.
The normal amounts of lithium in our bodies, and the concentrations given to the mice, are small — about 1,000 times lower than doses given to treat bipolar disorder, Yankner notes.
Yankner said he hoped toxicity trials of lithium salts would start soon. Neither he nor any of his co-authors have a financial interest in the outcome of the research, he said.
The National Institutes of Health was the major funder of the study, along with grants from private foundations.
'NIH support was absolutely critical for this work,' Yankner said.
The new research corroborates earlier studies hinting that lithium might be important for Alzheimer's. A large Danish study published in 2017 found people with higher levels of lithium in their drinking water were less likely to be diagnosed with dementia compared with those whose tap water contained naturally lower lithium levels. Another large study published in 2022 from the United Kingdom found that people prescribed lithium were about half as likely has those in a control group to be diagnosed with Alzheimer's, suggesting a protective effect of the drug.
But lithium's use in psychiatry caused it to become type cast as therapeutic, Yankner said. No one realized it might be important to the body's normal physiology.
That happened in part because the amounts of lithium that typically circulate in the body are so small, they couldn't be quantified until recently. Yankner and his team had to adapt new technology to measure it.
In the first stage of the research, the scientists tested the brain tissue and blood of older patients collected by the brain bank at Rush University for trace levels of 27 metals. Some of the patients had no history of memory trouble, while others had early memory decline and pronounced Alzheimer's. While there was no change in the levels of most metals they measured, lithium was an exception. Lithium levels were consistently lower in patients with mild cognitive impairment or Alzheimer's compared to those with normal brain function. The brains of patients Alzheimer's disease also showed increased levels of zinc and decreased levels of copper, something scientists had observed before.
Consistently finding lower lithium levels in the brains of people with memory loss amounted to a smoking gun, Yankner said.
'At first, frankly, we were skeptical of the result because it wasn't expected,' said Yankner.
But it held up even when they checked samples from other brain banks at Massachusetts General Hospital, Duke and Washington universities.
'We wanted to know whether this drop in lithium was biologically meaningful, so we devised an experimental protocol where we could take lithium selectively out of the diet of mice and see what happens,' Yankner said.
When they fed the mice a low-lithium diet, simply dropping their natural levels by 50%, their brains rapidly developed features of Alzheimer's.
'The neurons started to degenerate. The immune cells in the brain went wild in terms of increased inflammation and worse maintenance function of the neurons around them, and it looked more like an advanced Alzheimer patient,' Yankner said.
The team also found the gene expression profiles of lithium-deficient mice and people who had Alzheimer's disease looked very similar.
The researchers then started to look at how this drop in lithium might occur. Yankner said in the earliest stages there's a decrease in the uptake of lithium in the brain from the blood. They don't yet know exactly how or why it happens, but it's likely to be from a variety of things including reduced dietary intake, as well as genetic and environmental factors.
The major source of lithium for most people is their diet. Some of the foods that have the most lithium are leafy green vegetables, nuts, legumes and some spices like turmeric and cumin. Some mineral waters are also rich sources.
In other words, Yankner said, a lot of the foods that have already proven to be healthy and reduce a person's risk of dementia may be beneficial because of their lithium content.
'You know, oftentimes one finds in science that things may have an effect, and you think you know exactly why, but then subsequently turn out to be completely wrong about why,' he said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 minutes ago
- Yahoo
Strand Therapeutics Raises $153 Million Series B Financing to Further Advance Programmable mRNA Therapeutic Pipeline
Funding will advance Strand's pipeline and mission to bring targeted, next-generation mRNA therapies to patients First-in-human solid tumor Phase 1 data from lead program, STX-001, was recently presented at 2025 ASCO Annual Meeting BOSTON, August 07, 2025--(BUSINESS WIRE)--Strand Therapeutics, a leader in next-generation mRNA-based therapeutics, today announced $153M Series B funding led by Kinnevik, with new investors Regeneron Ventures, ICONIQ, Amgen Ventures, Alderline Group (the family office of Alex Gorsky), JIC-VGI, LG Technology Ventures, and Gradiant Corporation, with continued participation from existing investors including FPV Ventures, Playground Global, Eli Lilly and Company, ANRI, and Potentum. To date, Strand has raised over $250M. As part of the financing, Ala Alenazi, Ph.D., of Kinnevik, will join the company's Board of Directors. The funding will advance Strand's pipeline, led by STX-001, a programmable mRNA therapy that expresses the cytokine interleukin-12 (IL-12) directly from the tumor microenvironment. The company recently announced promising initial Phase 1 clinical data for patients with advanced solid tumors at the 2025 ASCO annual meeting, noting multiple RECIST responses (including cases of complete response and complete metabolic response), multiple cases of prolonged disease stabilization, and a favorable safety profile in treatment-resistant patients. Earlier this year, Strand also presented preclinical data for STX-003, a world-first systemically administrable mRNA therapy with tumor targeting that is programmed to avoid off-target payload delivery (including liver avoidance), showing the first glimpse into the massive potential of their programmable mRNA genetic circuits. Data presented at the 2025 AACR and ASGCT annual meetings demonstrated the candidate's potential to target expression of IL-12 to tumors following systemic administration of the LNP-mRNA drug, creating an effective anti-tumor therapy that was well tolerated. IL-12 is a potent pro-inflammatory cytokine primarily produced by antigen-presenting cells such as macrophages and dendritic cells. IL-12 holds significant promise in cancer immunotherapy due to its robust immunostimulatory effects. STX-001 encodes IL-12 which Strand has designed so that it can reprogram the tumor microenvironment and stimulate a systemic anti-tumor immune response. Unlike traditional mRNA therapies, Strand's approach uses self-replicating mRNA, ensuring localized and durable therapeutic activity. "We believe programmable RNA is the next frontier in therapeutics, and Strand has built the leading platform to unlock it," said Christian Scherrer, Senior Investment Director and Head of Health and Bio at Kinnevik. "Their early clinical data is outstanding, and the systemic delivery capability has the potential to reshape how we treat disease, starting with cancer, with more disease targets on the horizon. We look forward to partnering with founders Jake and Tasuku and the entire team as they move into this next phase of growth." "With support from our investors, we're advancing our vision of developing safe, effective, and accessible therapies through programmable genetic medicines, especially for those patients with few treatment options," said Jake Becraft, PhD, CEO and Co-founder of Strand Therapeutics. "Our initial STX-001 Phase 1 data provides early and strong clinical validation of our platform's capabilities. We have observed systemic immune activation and anti-tumor responses, including responses in non-injected lesions, across multiple tumor types. Now is an exciting period of expansion for our existing clinical work, as well as the exciting breakthrough assets in our pipeline, all with the potential to transform the treatment of cancer and other serious diseases." Strand's proprietary platform for programmable and potent mRNA therapeutics is the first of its kind. Its therapies combine best-in-class engineered next-generation mRNA modalities, such as self-replicating mRNA and circular RNA, with genetically programmed logic circuits, allowing for precise, controlled therapeutic payload delivery directly into the cells/tissues themselves. The novel approach brings the potential to effectively treat cancer and other deadly chronic diseases through its targeted therapies that are scalable, accessible, and expand the treatment landscape for patients desperately in need. About STX-001 STX-001 is an investigational multi-mechanistic, synthetic self-replicating mRNA technology that expresses an IL-12 cytokine for an extended period of time, directly administered to tumors in order to promote immune modulation and antitumor activity. The company received IND clearance from the U.S. Food and Drug Administration (FDA) in December 2023 to initiate a Phase 1/2 clinical trial for STX-001, announced its first patient dosed just before the 2024 ASCO Annual Meeting, and presented the first data of the trial at the 2025 ASCO Annual Meeting. Additional details can be found at using identifier: NCT06249048. About Strand Therapeutics Strand Therapeutics is leading the next generation of programmable mRNA therapies: where synthetic biology meets programmable biology to unlock the full potential of gene regulation and delivery inside the body. Unlike traditional mRNA technologies, Strand's platform programs RNA to think, enabling logic-controlled expression, precision delivery, and unprecedented control over therapeutic outcomes. Born out of MIT and led by world-class synthetic biologists, Strand is building the infrastructure to create medicines that respond to disease signals in real-time. With its computationally-driven design engine, self-amplifying/circular RNA modalities, and mRNA-only genetic circuits, the company is pioneering a new therapeutic modality poised to disrupt immuno-oncology, cell therapy, autoimmune diseases, and beyond. Strand's lead pipeline program, STX-001, is already in the clinic showing unprecedented response rates in late stage "salvage" cancer patients, with multiple patients showing RECIST responses. Strand's modular platform opens a broad horizon of partnership and licensing opportunities. Strand isn't just another mRNA company: it's the operating system for the programmable medicines of tomorrow. Follow us on LinkedIn and on X at @strandtx. View source version on Contacts Media contacts:Karen Sharmaksharma@ Shannia Coleyscoley@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10 minutes ago
- Yahoo
Natera Launches Fetal Focus™: A Noninvasive Prenatal Test for Inherited Conditions
Launch supported by strong assay performance in first milestone readout of the landmark EXPAND clinical trial AUSTIN, Texas, August 07, 2025--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced the launch of Fetal Focus, a noninvasive prenatal test (NIPT) for inherited conditions. When a pregnant patient is identified as a carrier of a recessive single-gene condition, medical guidelines recommend partner testing in order to determine the risk for the baby to be affected by the condition1; however, in some cases the biological father is unavailable for testing. The Fetal Focus test was designed to address this unmet need. Now if a pregnant patient tests positive with Natera's Horizon™ carrier screen for one of the five most commonly tested genes, and if the father is unavailable for testing, Fetal Focus can screen the fetus directly for that gene by simply analyzing a sample of the mother's blood. Fetal Focus is validated for the analysis of five genes: CFTR (cystic fibrosis), SMN1 (spinal muscular atrophy), HBA1 and HBA2 (alpha-thalassemia), and HBB (beta-hemoglobinopathies, including sickle cell disease). The launch is supported by data from EXPAND, a large, prospective, blinded clinical trial. The study, which was initiated in 2023, has enrolled approximately 1,300 participants to date, reflecting a diverse, multi-ethnic population from leading academic medical centers and maternal fetal medicine clinics. EXPAND is designed to be the defining clinical trial in the category, with all outcomes, including both positive and negative results, confirmed by genetic truth using prenatal or postnatal diagnostic testing. In its first milestone readout (n=101) from EXPAND, the Fetal Focus test demonstrated 91% sensitivity and successfully identified 5/5 fetuses affected by homozygous variants.2,3 Homozygous cases, where the fetus inherits the same condition-causing variant from both parents, are especially challenging to detect. Fetal Focus uses Natera's proprietary LinkedSNP™ technology to improve detection of these cases across diverse populations. "Having access to a noninvasive option like Fetal Focus can provide critical information to support decision-making during pregnancy, especially in situations where partner testing isn't possible," said John Williams, M.D., chief principal investigator for EXPAND and director of reproductive genetics at Cedars-Sinai. "Fetal Focus adds another important offering within our comprehensive reproductive health portfolio – furthering our commitment to launching products that address clinical gaps in care and are supported by rigorous clinical validation," said Sheetal Parmar, M.S., CGC, senior vice president of medical affairs for women's health at Natera. "The EXPAND study has been underway for several years, and we're pleased to release this first milestone readout." References ACOG Committee Opinion #690, Mar 2017. Internal data on file. In EXPAND, the study participants and investigators are blinded to the Fetal Focus™ test results. EXpanding Prenatal Cell Free DNA Screening Across MoNogenic Disorders (EXPAND). Accessed July 2025. About Natera Natera™ is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women's health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera's tests are supported by more than 300 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California. For more information, visit Forward-Looking Statements All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera's plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera's expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy and performance of our tests, or of the benefits of our tests and product offerings to patients, providers and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera's recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available at and View source version on Contacts Investor Relations: Mike Brophy, CFO, Natera, Inc., investor@ Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@ Sign in to access your portfolio
Yahoo
10 minutes ago
- Yahoo
Celcuity Inc. Schedules Release of Second Quarter 2025 Financial Results and Webcast/Conference Call
MINNEAPOLIS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the second quarter 2025 after the market closes on Thursday, August 14, 2025. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. Webcast and Conference Call InformationTo participate in the teleconference, domestic callers should dial 1-800-717-1738 and international callers should dial 1-646-307-1865. A live webcast presentation can also be accessed using this weblink: A replay of the webcast will be available on the Celcuity website following the live event. About Celcuity Celcuity is a clinical-stage biotechnology company pursuing development of targeted therapies for treatment of multiple solid tumor indications. The company's lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the PAM pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3Kα, AKT, or mTORC1 alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients. A Phase 1/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is ongoing. A Phase 3 clinical trial, VIKTORIA-2, evaluating gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2- advanced breast cancer is currently enrolling patients. More detailed information about Celcuity's active clinical trials can be found at Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at Follow us on LinkedIn and X. View source version of release on Contacts: Celcuity Inc. Brian Sullivan, bsullivan@ Vicky Hahne, vhahne@ (763) 392-0123 ICR HealthcarePatti Bank, (415) 513-1284Sign in to access your portfolio